Nabriva Therapeutics AG Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Nabriva Therapeutics are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Nabriva Therapeutics AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable basic indicators, Nabriva Therapeutics is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
| Begin Period Cash Flow | 47.8 M |
Nabriva |
Nabriva Therapeutics Relative Risk vs. Return Landscape
If you would invest (100.00) in Nabriva Therapeutics AG on December 24, 2024 and sell it today you would earn a total of 100.00 from holding Nabriva Therapeutics AG or generate -100.0% return on investment over 90 days. Nabriva Therapeutics AG is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Nabriva, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Nabriva Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Nabriva Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Nabriva Therapeutics AG, and traders can use it to determine the average amount a Nabriva Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| NBRV |
Based on monthly moving average Nabriva Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Nabriva Therapeutics by adding Nabriva Therapeutics to a well-diversified portfolio.
Nabriva Therapeutics Fundamentals Growth
Nabriva Stock prices reflect investors' perceptions of the future prospects and financial health of Nabriva Therapeutics, and Nabriva Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Nabriva Stock performance.
| Return On Equity | -2.69 | |||
| Return On Asset | -0.65 | |||
| Profit Margin | (1.48) % | |||
| Operating Margin | (1.29) % | |||
| Current Valuation | 3.29 M | |||
| Shares Outstanding | 3.2 M | |||
| Price To Earning | (0.48) X | |||
| Price To Book | 0.24 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 35.67 M | |||
| EBITDA | (54.7 M) | |||
| Cash And Equivalents | 20.04 M | |||
| Cash Per Share | 7.53 X | |||
| Total Debt | 5.22 M | |||
| Debt To Equity | 0.21 % | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (36.71 M) | |||
| Earnings Per Share | (19.67) X | |||
| Total Asset | 31.77 M | |||
| Retained Earnings | (652.86 M) | |||
| Current Asset | 83 M | |||
| Current Liabilities | 14 M | |||
Things to note about Nabriva Therapeutics performance evaluation
Checking the ongoing alerts about Nabriva Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Nabriva Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Nabriva Therapeutics is not yet fully synchronised with the market data | |
| Nabriva Therapeutics has some characteristics of a very speculative penny stock | |
| Nabriva Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 35.67 M. Net Loss for the year was (57.19 M) with loss before overhead, payroll, taxes, and interest of (10.23 M). | |
| Nabriva Therapeutics AG currently holds about 20.04 M in cash with (36.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.53. |
- Analyzing Nabriva Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Nabriva Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Nabriva Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Nabriva Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Nabriva Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Nabriva Therapeutics' stock. These opinions can provide insight into Nabriva Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Stocks Directory Find actively traded stocks across global markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |